Table 2.
Univariate | Multivariatea | |||
---|---|---|---|---|
Variable | OR (95% CI) | P-value | aOR (95% CI) | P-value |
Age | 1.06 (1.00–1.12) | 0.067 | ||
BMI | 1.09 (0.95–1.26) | 0.230 | ||
Preoperative PSA | 1.04 (1.02–1.06) | 4.63 × 10−4 | 1.03 (1.01–1.05) | 0.004 |
Prostate volume | 1.02 (0.99–1.05) | 0.118 | ||
PSA densityb | 3.59 (1.58–8.12) | 0.002 | ||
Clinical Gleason scoreb | 0.004 | |||
7 (3 + 4) vs ≤6 | 14.7 (1.45–148.0) | 0.023 | ||
7 (4 + 3) vs ≤6 | 22.0 (2.58–187.8) | 0.005 | ||
≥8 vs ≤6 | 40.3 (5.02–324.4) | 5.09 × 10−4 | ||
miR-636 | 0.65 (0.48–0.88) | 0.005 | 0.37 (0.23–0.61) | 9.92 × 10−5 |
miR-21 | 1.31 (1.07–1.61) | 0.009 | 1.65 (1.17–2.31) | 0.004 |
miR-16 | 1.34 (1.07–1.66) | 0.010 | ||
miR-142-3p | 1.12 (1.01–1.24) | 0.035 | ||
miR-451 | 1.42 (1.20–1.68) | 5.13 × 10−5 | 1.48 (1.15–1.90) | 0.002 |
112 PCa cases (75 localized and 37 metastatic) were used for analysis.
OR odds ratio, CI confidence interval, aOR adjusted odds ratio.
aMultivariate analysis was performed by logistic regression analysis with backward selection for preoperative PSA, miR-636, miR-21, miR-16, miR-142-3p, and miR-451.
bPSA density and clinical Gleason score were excluded for multivariate analysis.